New drug duo takes on recurrent brain cancer
NCT ID NCT07678684
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests whether an investigational drug called HF1K16, when combined with the approved drug bevacizumab, can help people with recurrent or progressive glioma—a type of brain tumor. The trial enrolls about 30 adults whose tumors have returned or worsened after prior treatment. Researchers will monitor tumor response, side effects, and how long participants live without the disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HF1K16 combined with bevacizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with recurrent or progressive glioma who have run out of standard therapies.
What could go wrong
This is an early Phase 2 study with only 30 participants, so results may not apply broadly. The combination may cause side effects or fail to slow tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact
Contact Email: •••••@•••••
Contact